Oban BioPharma

Coming – August 6

Disrupting The $70B GLP-1 Market

Date and Time

August 6

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

GLP-1 drugs have changed the way we treat diabetes and obesity, generating upwards of $70B in global sales in 2025. But they’re not perfect. Their use is often limited by nausea, and they cause the loss of muscle in addition to fat.

Oban BioPharma is developing a novel oral treatment for Type 2 diabetes and obesity that works across multiple pathways involved in metabolism at once. In contrast to current injectable drugs like Wegovy that work only on the GLP-1 receptor, Oban’s compounds hit six key targets at once, with a single small molecule that can be taken orally.

Early studies show this compound demonstrates greater than 90% reduction in food intake without signs of malaise/nausea, as well as fat-specific weight loss while preserving muscle.

Oban’s leadership team has a strong track record of building and exiting successful biotech companies, including prior acquisitions by major pharmaceutical firms. The two co-founders of Oban, with over 70 years of industry experience, were co-founders of four other companies valued at over $14 billion at exit, with each company having gone public and launched drugs into U.S/international markets.

Reserve your space today for this fireside chat with the executive team from Oban Pharma to hear how their unique approach to diabetes and weight loss is poised to disrupt a $70B market.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.